lung cancer

Pfizer
Biotech

Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial

The potential first-in-class ADC failed to significantly improve overall survival compared with docetaxel in previously treated nonsquamous NSCLC.
Angus Liu Jun 23, 2026 7:15am
rock geology mineral

Obsidian leverages Galera reverse merger to go public

Apr 14, 2026 11:20am
An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

Optellum tapped by NHS for AI-powered lung cancer diagnostic

Feb 2, 2026 8:55am
lung cancer

IceCure's treatment may extend survival in lung cancer patients

Nov 6, 2025 5:30am
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm
BioNTech

BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC

Sep 8, 2025 11:00am